Mother Nadja Cristina Gomes Bezerra displays a photograph she had taken for identification of her daughter Alice Vitoria Gomes Bezerra, 3-months-old, who has microcephaly, on January 31, 2016 in Recife, Brazil. In the last four months, authorities have recorded close to 4,000 cases in Brazil in which the mosquito-borne Zika virus may have led to microcephaly in infants.
Mother Nadja Cristina Gomes Bezerra displays a photograph she had taken for identification of her daughter Alice Vitoria Gomes Bezerra, 3-months-old, who has microcephaly, on January 31, 2016 in Recife, Brazil. In the last four months, authorities have recorded close to 4,000 cases in Brazil in which the mosquito-borne Zika virus may have led to microcephaly in infants. - 
Listen To The Story
Marketplace

The World Health Organization convenes an emergency meeting Monday to help determine its response to the Zika virus.

There’s no widely available test for the mosquito-borne illness linked to birth defects, and even the most optimistic estimates say a vaccine won’t be available until late 2016.

Developing a vaccine is no small feat. First, you need a lot of cash, said Dr. Ken Kaitin at the Tufts Center for the Study of Drug Development.

“It could take close to $1 billion to bring one successful compound to market,” he said.

Then, Kaitin said, given that pregnant women are at risk, that complicates the process for drug makers.

“In anything that’s dealing with pregnancy or children for that matter, you have an added obstacle because you don’t want to create a bigger problem then you are trying to cure,” he said.

A few of the biggest drug companies in the world are exploring vaccine development, including GlaxoSmithKline and Sanofi.

The Zika virus could infect some 4 million people in the Americas, and that’s why Sanofi’s Dr. Paul Beninger hopes U.S. health officials round up all the pharmaceutical executives and put the screws to them.

“Putting the finger to every person in the room and say I need your help to do this. And I think people respond to that. It’s when they aren’t identified it doesn’t happen,” he said.

Beninger said as we saw with Ebola, the capacity to develop a vaccine is there. It’s just a question of unlocking it.

“I think the best compliment I can give is not to say how much your programs have taught me (a ton), but how much Marketplace has motivated me to go out and teach myself.” – Michael in Arlington, VA

As a nonprofit news organization, what matters to us is the same thing that matters to you: being a source for trustworthy, independent news that makes people smarter about business and the economy. So if Marketplace has helped you understand the economy better, make more informed financial decisions or just encouraged you to think differently, we’re asking you to give a little something back.

Become a Marketplace Investor today – in whatever amount is right for you – and keep public service journalism strong. We’re grateful for your support.

Follow Dan Gorenstein at @dmgorenstein